Clinical trial
Study of Investigational Drug in Osteoporosis (MK-0217-908)
NCT00092053 · Organon and Co, Industry · Completed
Key facts
| NCT number | NCT00092053 |
|---|---|
| Title | Study of Investigational Drug in Osteoporosis (MK-0217-908) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Persistence of the Effect of Oral Monthly Ibandronate on Bone Reception in Postmenopausal Women in Osteoporosis |
| Lead sponsor | Organon and Co, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Postmenopausal Osteoporosis |
| Intervention type | Drug |
| Interventions | Placebo, ibandronate |
| Enrollment | 203 |
| Start date | Dec 1, 2004 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 24, 2004 |
| Last update posted | Feb 2, 2022 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: